Tweet
dBTechno
<img alt="" height="1" width="1" />
Basilea Vows Strategy Review Amid Antibiotic Setback
Wall Street Journal
ZURICH (Dow Jones)--Basilea Pharmaceutica AG (BSLN.EB) saw nearly one-fifth of its market capitalization sliced off after the company said it would have to review its options because of a setback to a key, ...
Basilea superbug drug hits FDA hurdle, shares dropReuters
Basilea Drops After US Regulators Reject AntibioticBloomberg
FDA asks J&J for more studies on antibioticBusinessWeek
MarketWatch -RTT News -dBTechno
all 59 news articles »
More...